{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T10:35:40Z","timestamp":1753180540323},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1007\/s10557-005-1375-1","type":"journal-article","created":{"date-parts":[[2005,9,4]],"date-time":"2005-09-04T12:55:21Z","timestamp":1125838521000},"page":"197-201","source":"Crossref","is-referenced-by-count":11,"title":["The HOPE TIPS: The HOPE Study Translated into Practices"],"prefix":"10.1007","volume":"19","author":[{"given":"Norman","family":"Sharpe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1375_CR1","volume-title":"The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020","year":"1996","unstructured":"Murray CJL, Lopez AD, eds. The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston: Harvard School of Public Health, 1996."},{"key":"1375_CR2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, \u00d4unpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937\u2013953.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1375_CR3","first-page":"S11","volume":"10","author":"Third Joint Task Force of the European and other Societies","year":"2003","unstructured":"Third Joint Task Force of the European and other Societies. European guidelines on cardiovascular disease prevention in clinical practice. New Euro J CV Prev and Rehab 2003;10(Suppl 1):S11\u2013S78.","journal-title":"New Euro J CV Prev and Rehab"},{"key":"1375_CR4","unstructured":"New Zealand Guidelines Group. The Assessment and Management of Cardiovascular Risk. December 2003."},{"key":"1375_CR5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"Heart Outcomes Prevention Evaluation (HOPE) study investigators","year":"2000","unstructured":"Heart Outcomes Prevention Evaluation (HOPE) study investigators. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145\u2013153.","journal-title":"N Engl J Med"},{"key":"1375_CR6","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"KM Fox","year":"2003","unstructured":"Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary heart disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782\u2013788.","journal-title":"Lancet"},{"key":"1375_CR7","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","volume":"351","author":"The PEACE Trial Investigators","year":"2004","unstructured":"The PEACE Trial Investigators. Angiotensin converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058\u20132068.","journal-title":"N Engl J Med"},{"key":"1375_CR8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","unstructured":"Antithrombotic Trialists\u2019 Collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002;324:71\u201386.","journal-title":"BMJ"},{"key":"1375_CR9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","volume":"27","author":"S Yusuf","year":"1985","unstructured":"Yusuf S, Peto R, Lewis J, et al. Beta-blockade during and after myocardial infarction: An overview of the randomised trials. Prog Cardiovasc Dis 1985;27:335\u2013371.","journal-title":"Prog Cardiovasc Dis"},{"key":"1375_CR10","first-page":"1383","volume":"334","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival (4S) Study. Lancet 1994;334:1383\u20131389.","journal-title":"Lancet"},{"key":"1375_CR11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/euhj.2000.2459","volume":"22","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Clinical, public health and research implications of the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J 2001;22:103\u2013104.","journal-title":"Eur Heart J"},{"key":"1375_CR12","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1742-1241.2002.tb11374.x","volume":"56","author":"N Sharpe","year":"2002","unstructured":"Sharpe N. Matching the standards of clinical trial evidence with application in practice. Int J Clin Pract 2002;56:772\u2013775.","journal-title":"Int J Clin Pract"},{"key":"1375_CR13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0149-2918(96)80216-5","volume":"18","author":"NM Kaplan","year":"1996","unstructured":"Kaplan NM. The CARE study, a postmarketing evaluation of ramipril in 11,100 patients. Clin Ther 1996;18:658\u2013670.","journal-title":"Clin Ther"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-005-1375-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-005-1375-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-005-1375-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T10:23:19Z","timestamp":1683195799000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-005-1375-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["1375"],"URL":"https:\/\/doi.org\/10.1007\/s10557-005-1375-1","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}